Skip to content
HowShorted

Avalo Therapeutics, Inc. short interest in 2021

In 2021, Avalo Therapeutics, Inc.'s disclosed short interest ran from 2.52% of shares outstanding on 15 Jan 2021 to 1.38% on 31 Dec 2021, a change of -1.14 percentage points. The year's high was 3.23% on 15 Oct 2021 and its low 1.38% on 31 Dec 2021, averaging 2.28% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.12 days on 29 Oct 2021. Full history: Avalo Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Avalo Therapeutics, Inc. in 2021

2021 in figures

Start of year
2.52% (15 Jan 2021)
End of year
1.38% (31 Dec 2021)
Change
-1.14 pp
High
3.23% (15 Oct 2021)
Low
1.38% (31 Dec 2021)
Average
2.28%
Highest days to cover
9.12 (29 Oct 2021)
SEC filings marked
9

Every report in 2021

Avalo Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20212.52%1.14results (8-K)
29 Jan 20212.49%1.26
12 Feb 20212.56%2.32
26 Feb 20211.96%1.67
15 Mar 20211.87%2.5810-K filed, results (8-K)
31 Mar 20211.93%4.94
15 Apr 20211.89%3.25
30 Apr 20212.58%3.57
14 May 20212.71%1.0010-Q filed, results (8-K)
28 May 20212.54%2.48
15 Jun 20212.25%2.09
30 Jun 20212.69%3.20
15 Jul 20212.60%7.30
30 Jul 20212.43%3.13
13 Aug 20212.49%5.5510-Q filed, results (8-K)
15 Oct 20213.23%6.23
29 Oct 20213.08%9.12
15 Nov 20211.67%6.7710-Q filed, results (8-K)
30 Nov 20211.58%5.63
15 Dec 20211.47%5.33
31 Dec 20211.38%3.71

See also: Avalo Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.